Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests on average 25% of its turnover (excluding generics) every year in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
Role within Project
- Non clinical safety expertise for the development and validation of biomarkers for nonclinical prediction of immune-mediated safety issues
- Contribution to WP 2 “Immuno-Oncology Models“ (iAOP, surveys…)
- Contribution to WP3 “Innovative models for safety assessment of immune-inflammatory disease therapeutics” (iAOP, surveys…)